Liangyihui

The firm operates a comprehensive digital platform designed to address information asymmetry within the cancer treatment landscape. Its business model centers on connecting key stakeholders: pharmaceutical companies, physicians, hospitals, and patients. For healthcare professionals, Liangyihui offers a platform for continuing education, access to the latest research, case studies, and opportunities for professional branding. For patients, it provides access to credible information, expert consultations, and support services. Revenue is generated by providing digital marketing and service solutions to pharmaceutical companies, helping them to effectively reach and educate their target audience of oncology professionals and patients. The company reports that it has achieved profitability.

Liangyihui's service portfolio is delivered through a matrix of digital products, including the "Oncology Doctor" App, "Oncology Information" and "Patient Guide" WeChat public accounts, and an internet hospital platform. These tools aim to digitize and streamline traditionally offline activities like medical education, patient services, and pharmaceutical marketing. The platform has amassed a substantial user base, reportedly including nearly 200,000 oncology doctors and 300,000 patients. In a move to further leverage its data and user network, the company initiated the development of a large AI model in February 2024. This strategic initiative is intended to enhance its service offerings and create more efficient solutions for clinical management and patient care within the oncology field.